Revolutionizing treatment
decisions for coronary
artery disease.

Quick, non-invasive,
wire-free 3D FFR guidance.

Learn More

Introducing the Cathworks

FFRangio® System
FFRangio system

Confident answers for coronary artery disease.

Transform routine angiograms into objective multi-vessel physiologic, and anatomic insights, giving you the information you need to optimize PCI treatment decisions.

Sorry, your browser does not support inline SVG.

Elevate your practice with the proven benefits of FFR.

FFRangio delivers highly accurate multi-vessel FFR results without the need for an invasive pressure wire or hyperemic stimulus, making important FFR benefits practical for more patients.

FAME study: FFR-guided PCI improves outcomes and saves cost compared to angiography-guided PCI.

  • 30%

    Reduction in stents per patient*

  • 28%

    Relative Reduction in 1-year clinical events*

  • 14%

    Reduction in costs at 1-year**

See How FFRangio Works

Physician Perspectives

TCT 2022: Dr. Martin B. Leon, Prof. Ran Kornowski, Dr. Rahul P. Sharma and Dr. Amir Kaki share how they’ve integrated the FFRangio System in their cath labs and explain why it’s poised to be the new standard of care in physiology assessment.

Watch the TCT 2022 panel arrow_forward
play_arrowPlay Now

CathWorks FFRangio® System: A New Era in Coronary Physiology

Dr. Martin B. Leon, Prof. Ran Kornowski, Dr. Rahul P. Sharma and Dr. Amir Kaki

play_arrowPlay Now

FFRangio in Clinical Practice

Dr. Rahul P. Sharma

Stanford Healthcare

play_arrowPlay Now

FFRangio Compared to FFR Clinical Data

Dr. William F. Fearon

Stanford University Medical Center, California

play_arrowPlay Now

Applicability of FFRangio in Serial Lesions Diffuse Disease

Dr. Carlos Collet Bortone

the Cardiovascular Center OLV AALST, Belgium

play_arrowPlay Now

FFRangio in Routine Clinical Practice US Experience

Dr. Rahul P. Sharma

Stanford University Medical Center, California

“FFRangio has the potential to eventually replace wire-based FFR measurement and substantially increase physiological coronary lesion assessment in the catheterization laboratory, thereby leading to improved patient outcomes”

View Clinical Studies arrow_forward

FAST-FFR Trial: Fearon WF, et al. Circ. September 2018. 10.1161/CIRCULATIONAHA.118.037350.



TCT 2019

San Francisco, CA

Room 203,
Level 2 Moscone South,
Moscone Center
Event Details View All Events arrow_forward

Find out more.


    Regulatory Status

    The CathWorks FFRangio® System has received United States 510(k) clearance, Europe CE approval, Israel Amar approval, and Japan PMDA approval.

    *Tonino et al. N Engl J Med. January 15, 2009; 360:213-224;
    **Fearon et al. Circulation. 2010;122:2545-2550;

    expand_lessBack to top of page

    We use cookies to enhance your experience. By continuing to visit this site, you agree to our use of cookies. Terms and Conditions